AU2001259215A1 - Human anti-cd40 antibodies and methods of making and using same - Google Patents

Human anti-cd40 antibodies and methods of making and using same

Info

Publication number
AU2001259215A1
AU2001259215A1 AU2001259215A AU5921501A AU2001259215A1 AU 2001259215 A1 AU2001259215 A1 AU 2001259215A1 AU 2001259215 A AU2001259215 A AU 2001259215A AU 5921501 A AU5921501 A AU 5921501A AU 2001259215 A1 AU2001259215 A1 AU 2001259215A1
Authority
AU
Australia
Prior art keywords
antibodies
making
methods
same
human anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259215A
Inventor
Xingjie Chen
Toshifumi Mikayama
Stephen P. Schoenberger
Nobuaki Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Institute for Allergy and Immunology
Original Assignee
Kirin Pharma USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Pharma USA Inc filed Critical Kirin Pharma USA Inc
Publication of AU2001259215A1 publication Critical patent/AU2001259215A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
AU2001259215A 2000-04-28 2001-04-27 Human anti-cd40 antibodies and methods of making and using same Abandoned AU2001259215A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20060100P 2000-04-28 2000-04-28
US60200601 2000-04-28
PCT/US2001/013672 WO2001083755A2 (en) 2000-04-28 2001-04-27 Human anti-cd40 antibodies and methods of making and using same

Publications (1)

Publication Number Publication Date
AU2001259215A1 true AU2001259215A1 (en) 2001-11-12

Family

ID=22742393

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259215A Abandoned AU2001259215A1 (en) 2000-04-28 2001-04-27 Human anti-cd40 antibodies and methods of making and using same

Country Status (3)

Country Link
AU (1) AU2001259215A1 (en)
TW (1) TWI264467B (en)
WO (1) WO2001083755A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP4271440B2 (en) * 2000-10-02 2009-06-03 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Human anti-CD40 antibody
WO2002036166A2 (en) * 2000-11-03 2002-05-10 The University Of South Florida Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease
EP2009027B1 (en) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
WO2003029296A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
WO2003028809A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Methods of therapy for b-cell malignancies
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
CA2466931A1 (en) * 2001-11-26 2003-06-05 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
PL1684805T3 (en) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
EP2243491A1 (en) * 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
ATE447412T1 (en) * 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES AND METHODS OF USE
JP4810431B2 (en) * 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Method for treating cancer associated with B cells
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2006073443A2 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
ES2400660T3 (en) 2005-11-01 2013-04-11 Novartis Ag Uses of anti-CD40 antibodies
MEP39508A (en) 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
JP5730576B2 (en) 2007-11-07 2015-06-10 ジェネンテック， インコーポレイテッド Methods and compositions for assessing B cell lymphoma responsiveness to treatment with anti-CD40 antibodies
AU2010222929B2 (en) 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
JP2012511014A (en) * 2008-12-05 2012-05-17 エイエルエス・セラピー・デベロップメント・インスティテュート Methods for treating neurodegenerative diseases
US9562104B2 (en) 2009-03-10 2017-02-07 Baylor Research Institute Anti-CD40 antibodies
DK2406289T3 (en) 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
CA2758523C (en) 2009-04-18 2019-03-12 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
TW201300418A (en) 2011-03-25 2013-01-01 Baylor Res Inst Compositions and methods to immunize against hepatitis C virus
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
MX2017001864A (en) 2014-08-12 2017-08-02 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies.
MA41459A (en) 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
CN109069622A (en) 2015-09-30 2018-12-21 詹森生物科技公司 Specifically bind the antagonistic antibodies and application method of people CD40
MA45488A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, KITS AND APPARATUS
BR112018008904A2 (en) 2015-11-03 2018-11-27 Janssen Biotech Inc antibodies specifically binding to tim-3 and their uses
TWI784957B (en) 2016-06-20 2022-12-01 英商克馬伯有限公司 Immunocytokines
EP3497120A1 (en) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
CN109843916B (en) 2016-08-12 2023-10-31 詹森生物科技公司 Fc-engineered anti-TNFR superfamily member antibodies with enhanced agonistic activity and methods of use thereof
BR112019022356A2 (en) 2017-04-27 2020-05-26 Juno Therapeutics Gmbh OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF
AU2018271915A1 (en) 2017-05-24 2019-11-28 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
CN111344304B (en) * 2017-06-01 2023-09-01 Pb免疫治疗公司 Novel anti-CD 40 antibodies and uses thereof
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
AU2019328575A1 (en) 2018-08-30 2021-02-25 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
JP7397874B2 (en) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド Multichain chimeric polypeptides and their uses
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN109678959B (en) * 2019-02-22 2020-12-08 北京免疫方舟医药科技有限公司 anti-CD 40 antibodies and uses thereof
US11738052B2 (en) 2019-06-21 2023-08-29 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0651797B1 (en) * 1992-07-09 2004-01-28 Chiron Corporation A method for generation of antibodies to cell surface molecules
KR960704576A (en) * 1993-10-01 1996-10-09 크리스토퍼 엘. 와이트 Antibodies to CD40
ES2304786T3 (en) * 1995-04-27 2008-10-16 Amgen Fremont Inc. ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
EP0823941A4 (en) * 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
WO2000000156A2 (en) * 1998-06-26 2000-01-06 Trustees Of Dartmouth College Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands

Also Published As

Publication number Publication date
WO2001083755A3 (en) 2002-05-23
TWI264467B (en) 2006-10-21
WO2001083755A2 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU2001259215A1 (en) Human anti-cd40 antibodies and methods of making and using same
AU2001261160A1 (en) Prosthesis and method of making
ZA200305825B (en) Modified antibodies and methods of use
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU2002320456A1 (en) Removable stent and method of using the same
IL206980A0 (en) Antibodies that bind human interleukin-18 and methods of making and using
AU2001270943A1 (en) Surgical instrument and method of using the same
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU2002314466A1 (en) Withasol and methods of use
AU2001251358A1 (en) Prion-binding ligands and methods of using same
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001272840A1 (en) Adjustable chair and method of use
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2002324965A1 (en) Artificial kidney and methods of using same
AU2002326751A1 (en) Immunoglobulin e vaccines and methods of use thereof
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU2002211183A1 (en) Prosthetic construct and methods for its manufacture and use
AU2001260774A1 (en) Bio-support and preparing method of the same
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
HK1046646A1 (en) Preparations and method of producing the same
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2001261375A1 (en) Human caspase-12 materials and methods
AU2002310237A1 (en) Sponge-derived terpenoids and methods of use
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same